UK markets close in 4 hours 33 minutes

Photocure ASA (0IMT.L)

LSE - LSE Delayed price. Currency in NOK
Add to watchlist
59.500.00 (0.00%)
As of 02:52PM BST. Market open.
Full screen
Previous close59.50
Open0.00
Bid0.00 x 0
Ask0.00 x 0
Day's range0.00 - 0.00
52-week range
Volume8,299
Avg. volume2,783
Market cap11.635M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-2.53
Earnings date07 Aug 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • PR Newswire

    Photocure ASA - Annual general meeting held

    Photocure ASA (OSE: PHO), held its annual general meeting on 23 May 2024 at 17:00 hours (CEST).

  • PR Newswire

    Photocure ASA: Results for the first quarter of 2024

    Photocure ASA (OSE:PHO) today reported Hexvix®/Cysview® revenues of NOK 116.8 million in the first quarter of 2024 (Q1 2023: NOK 105.9 million), and EBITDA of NOK 7.9 million (NOK -1.2 million) following positive operational developments and cost control. The Company reiterates its business and financial guidance for 2024 with 40 to 70 new and upgraded Saphira™ blue light tower installations during the year, product revenue growth of 6% to 9% in constant currency, and positive EBITDA excluding b

  • PR Newswire

    Photocure Partner Asieris announces New Drug Application acceptance for regulatory review of Cevira in China

    Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) communicated today that the National Medical Products Administration (NMPA) has accepted its new drug application (NDA) for the regulatory review of Cevira® (APL-1702, Hexaminolevulinate Hydrochloride Ointment Photodynamic Therapy System) for potential marketing authorization in China. Cevira (APL-1702) is a photodynamic drug-device combination product in development for the non